The EFSA Panel on Nutrition, Novel foods and Food Allergens (NDA) just published a scientific opinion on chia seeds (Salvia hispanica L.) powders as novel foods (NFs) pursuant to Regulation (EU) 2015/2283. According to the EFSA panel, the partially defatted powders of whole chia seeds are considered safe under the assessed conditions of use. [...]
NEWS DIGEST by a&r | June 2019 We dedicate this issue to regulatory news on EFSA new scientific opinion on Chia powders. Also, an overview on current mergers and acquisitions (M&A) in the sector is provided. […]
EFSA will extend their dedicated services to applicants from small and medium-sized enterprises (SMEs). SMEs will now be able to access support from EFSA when preparing, submitting, and monitoring their applications for regulated products. EFSA will use the experience gained in providing these new forms of support to decide whether to include them in [...]
Vitafoods Europe is the perfect place to learn what is happening in the nutraceutical market. The show offers an excellent opportunity to engage in in-depth conversations with clients about opportunities in natural health products innovation. We hope you were able to find some time to stop by our booth and meet the team. We [...]
a&r’s News Digest – We dedicate this May issue to Vitafoods Europe and some general news. Also, we have decided to repeat our seminar on the regulatory challenges for CBD-based products in the EU. Join us in June! […]
The new regulation on mutual recognition EU 2019/515 will enter into force on 19 April 2020 and will repeal the current EC 764/2008. According to the new regulation, member states will have to accept products that are lawfully marketed in another member state unless they can prove that the product poses a serious risk [...]
A recent warning by the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) states that diabetics, pregnant women, children, and those with certain food allergies should stop taking joint health supplements containing glucosamine and/or chondroitin sulfate due to a risk of adverse events. This statement comes as a result of an [...]
analyze & realize GmbH, a regulatory expert for natural health products, offers a seminar on the current regulatory situation for cannabidiol-containing food products in the EU. The interactive seminar provides an overview on the regulatory challenges that food business operators currently face and will explain the requirements for the submission of Novel Food applications [...]
Earlier this year, Food Supplements Europe (FSE) released an update of the Novel Food Guideline from 2018 on how to verify the novel food status under the Novel Food Regulation (EU) 2015/2283 (NFR), which considers the developments and experiences after 1 year of application of this regulation. The main goal of this guidance document [...]
EFSA has again rejected the health claim (under article 14) related to Nutrimune and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT) from H.J. Heinz Supply Chain Europe B.V.. Nutrimune is a pasteurised cow’s skim milk fermented with Lactobacillus paracasei CBA L74. The claimed effect proposed by the [...]
MeriCal, a contract manufacturer and packager of high quality probiotics and nutritional supplements, has recently signed a final commercial agreement to acquire Global Health Industries (GHI).
GHI is highly specialized in the manufacturing of probiotics. MeriCal’s acquisition of GHI will increase market competitiveness and will drive international expansion.
It has been reported by Bloomberg that Nestle is currently the top bidder for Merck KGaA’s, offering up to $5 billion. According to the sources, companies previously interested in this business have dropped out of the bidding, including Perrigo and Bain and Cinven, while Reckitt Benckiser and Mylan are still in the running. Nestle, frontrunner at the moment, has been strengthening its health business, and acquired Atrium Innovations for $2.3 billion last month.
Global ingredients company DSM has acquired Biocare Copenhagen, expanding their gut health portfolio for an undisclosed price. With this acquisition, DSM will increase its gut health portfolio with probiotics. The company has showed interest in gut health ingredients beyond the well-known indications for digestive and immune health.
Earlier this month, Nestlé announced that it agreed to acquire Atrium Innovations (transaction to be completed Q1 2018). Atrium is globally recognized for the development, production, and commercialization of innovative and scientifically-proven natural health products. Its strategy is complementary with Nestlé science-based natural solutions for consumers and health care professionals. With this acquisition, Nestlé will extend its consumer healthcare nutrition portfolio, and Atrium will compete more effectively in the global market place.
A clear evidence that silos between industries will be breaking down in the future.
Walgreens has announced that it will invest $416 million to acquire 40% stake in Sinopharm Holding GuoDa Drug Store Co., Ltd (GuoDa). Walgreens is the second-largest pharmacy store chain in the US behind CVS Health. GuoDa retails pharmaceutical and healthcare products across China.
Walgreens was already present in China through Alliance Boots. This new investment highlights the interest of Walgreens in the Chinese fast-paced retail pharmacy business.
Walgreens investment took place in the same week that CVS announced to spend $69 billion to buy Aetna, the third largest health insurer in the U.S. CVS also has international operations but has not revealed interest in China yet.
Frutarom licensed AB-FORTIS in 2012 and now is buying the patent. AB-Fortis is a micro-encapsulation system that allows delivering 100% of the recommended daily amount of iron in a single dose, with high bioavailability and no adverse effects in taste or during digestion. “AB-Fortis expands Frutarom’s diverse product portfolio in the growing field of specialty healthy ingredients,” says Dr Raimund C. Hoenes, General Manager of Frutarom Health. With this transaction, AB-BIOTICS will focus on its probiotics business, which represents 87% of its total sale. In addition, the sales of AB-FORTIS will support the great R&D investment that AB-BIOTICS has done to reinforce their current probiotics concepts.
Relevium has signed a non-binding agreement to acquire an American nutraceutical e-brand that sell their products mainly through Amazon.
Relevium is a publicly traded company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness market. The value of this transaction is currently estimated at 1,15 mill EUR and it is foreseen to be closed on the 30th of November this year.
Last summer, Relevium completed the acquisition of BioGanix, another e-commerce brand and they have plans to conclude more transactions with e-retail brands in the future.
In September, color-ingredients manufacturer Roha (India) completed the acquisition of New Foods Industry S.p.A., an Italian company.
Roha is a leader in the color-ingredients market worldwide, and New Foods Industry is specialized in dry ingredients for the food and beverage industries.
This is the third acquisition for Roha during this year, enabling its further consolidation in the color business.